Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation. (PubMed, Heart Lung) - Oct 2, 2026 - "Post-marketing data are valuable for determining the long-term safety of medications, and further studies confirming the cardiovascular AE signals identified in this study may yield insights into the cardiovascular safety of these monoclonal antibodies."
Adverse events • Journal • Asthma • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Eosinophilia • Heart Failure • Hematological Disorders • Hypertension • Hypotension • Immunology • Inflammation • Myocardial Infarction • Pulmonary Disease • Respiratory Diseases • Thrombosis
|